Galectin Therapeutics (GALT) 10-Q2012 Q1 Quarterly report

Filed: 11 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: affinity, aim, amelioration, approach, argument, ASC, assist, attempt, attempting, Belgian, block, Blocking, Bulletin, capable, Centre, chose, clause, Colombian, commitment, component, contest, Counter, cover, creation, criteria, deadly, deliver, derivative, derived, developmental, discount, enrolled, enrollment, essential, Europe, evasion, exploring, factor, FAMHP, fatty, Finally, fractional, GALT, GALTU, GALTW, globular, greatest, halted, high, highly, immune, implicated, incapable, indicia, inflammation, insult, intensive, interaction, invasion, kidney, lack, lacking, leverage, linear, locally, lung, Luxembourg, main, mannose, mice, NASDAQ, NASH, offer, offering, oncology, open, OTCBB, partially, partnership, plant, play, polymer, possessing, precisely, preliminary, progressed, progression, prominent, promoting, proposed, proprietary, pursuit, recently, recommended, regimen, relevant, relisted, resistant, retroactively, rounded, salutary, Seventeen, skin, source, split, stopped, strategic, strongly, suggested, symbol, top, Topic, toxin, underwriting, underwritten, unresectable, vigorously

Removed: absorption, active, acute, administer, advance, affecting, afflicted, agent, amended, anniversary, announced, annually, annum, apply, area, attributable, August, authorized, automatic, automobile, awarded, back, Baylor, bifurcation, bile, blinded, breast, calculate, calculating, calendar, carbohydrate, care, Certificate, characterize, classified, closed, collagen, commenced, compassionate, compel, consecutive, constituting, continuing, controlled, convert, cultured, customary, deemed, delete, dental, design, designated, Designation, designed, diseased, dissolution, Division, duct, duly, earlier, embedded, equal, experienced, expression, extended, extension, feature, fewer, fibrogenic, file, fiscal, Floor, forfeiture, formation, Foundation, fourth, freight, Friedman, gastrointestinal, generating, GlaxoSmithKline, great, greater, hepatic, higher, holder, hospitalization, improve, increase, increasing, infection, injury, innovative, insert, investigation, Investigational, involuntarily, isolate, iv, laboratory, largest, leading, licensing, liquidation, Mandatory, manner, markedly, maximum, median, medical, met, mezzanine, monthly, Mount, multiplied, noting, original, par, patent, payout, Pennsylvania, percentage, performed, permanent, Peter, physical, pioneering, pivotal, placement, preference, presented, President, prevailing, prevalence, problem, production, productive, QTDP, Qualifying, quality, randomized, rat, reached, receivable, redeem, redeemed, redemption, reduced, reducing, reflected, remained, remove, renal, request, restated, resulting, return, reversed, revert, ROI, salary, scarring, School, Scott, screened, Section, semi, Senior, shareholder, shipping, showed, significantly, Sinai, solid, solution, space, Specifically, standard, stellate, stream, subordinate, summary, target, tax, team, termination, testing, thirty, tolerated, toxic, toxicity, Traber, transfer, transplant, type, unadjusted, Uncontrolled, underlying, unissued, University, unpaid, vesting, Vice, viral, vitro, vivo, voluntarily, voting, widely, winding, world, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

GALT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas A. McGauley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 11, 2012		/s/ Thomas A. McGauley
	Name:	Thomas A. McGauley
	Title:	Chief Financial Officer
		(principal financial and accounting officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.